GlassScriptPhysician profile
Ricardo Alvarez
NPI 1417078031
$14,650.04
in general payments reported to CMS, 2019-2025
57 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,479 · 2020: $3,407 · 2021: $1,340 · 2022: $1,287 · 2023: $1,297 · 2024: $1,226 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $4,270.73 | 2019-2025 | Korlym |
| Puma Biotechnology, INC. | $1,500.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,002.21 | 2019-2022 | |
| Novo Nordisk INC | $852.72 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $849.64 | 2022-2025 | |
| Abbott Laboratories | $800.61 | 2019-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Amgen INC. | $701.83 | 2019-2025 | Repatha, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.14 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $431.66 | 2019-2023 | |
| Esperion Therapeutics, INC. | $348.76 | 2021-2024 | Nexletol |
| Lilly USA, LLC | $274.86 | 2020-2023 | Mounjaro, Jardiance, Humulin |
| Ibsa Pharma INC. | $251.04 | 2019-2023 | Tirosint, Licart |
| Medtronic Minimed, INC. | $217.64 | 2019-2020 | |
| Antares Pharma, INC. | $216.82 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Radius Health, INC. | $210.55 | 2019-2025 | Tymlos |
Show all 53 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.